Sunday, July 21, 2024

Latest Posts

Weight reduction shares ought to seize huge features, Tema ETFs’ CEO suggests


Weight loss now its own segment... with its own ETFs?

Tema ETFs has been capitalizing on the danger urge for food for weight reduction shares.

It’s behind the GLP-1, Weight problems & Cardiometabolic ETF (HRTS), which is up 26% since its inception final November.

The agency’s founder and CEO Maurits Pot thinks the profitable weight reduction commerce is not based mostly on simply hype.

“The businesses we monitor and the businesses we spend money on are wanting not simply at a weight reduction strategy, but in addition different approaches,” Pot informed CNBC’s “ETF Edge” on Monday. “We may see a world the place the vast majority of the world’s inhabitants takes a GLP-1, not only for weight reduction, however for different ailments.”

His prime holdings embrace Mounjaro producer Eli Lilly and Ozempic and Wegovy maker Novo Nordisk. Eli Lilly is up 57% to this point this yr, whereas Novo Nordisk is up 38%.

Plus, Pot doesn’t count on the worth tag for GLP-1s to discourage new sufferers. He thinks they’ll come down considerably within the subsequent two to 3 years.

“We may see drug pricing come down from $12,000 to possibly $6,000 a yr, so possibly $500 a month,” mentioned Pot, who factors out insurance coverage protection typically makes the therapies extra inexpensive to sufferers.

Latest Posts

Stay in touch

To be updated with all the latest news, offers and special announcements.